Skip to main content
Premium Trial:

Request an Annual Quote

Sigma-Aldrich Acquires Protein Research Technology from GenWay Biotech

NEW YORK (GenomeWeb News) – Sigma-Aldrich today said that it has expanded its proteomics research products offerings through the acquisition of the Seppro affinity depletion technology and a library of 700 avian-derived antibodies from GenWay Biotech.
 
The Seppro products enable scientists to measure more precisely the expression of protein biomarkers from a range of mammalian and plant biological samples, said Sigma. The technology allows researchers to detect and analyze commonly obscured biomarkers in samples by removing highly abundant proteins.
 
The acquisition includes current inventory, production technology, and all future rights to produce and distribute the product lines, said Sigma. It adds to the firm’s current depletion product offerings, such as its ProteoPrep kits for the removal of highly abundant proteins from human serum and plasma.
 
The St. Louis-based firm said that the library of 700 polyclonal IgY antibodies acquired from San Diego-based GenWay marks its first IgY antibody offering.
 
Further terms of the acquisition were not provided.

The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.